Boothbay Fund Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Boothbay Fund Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,865,000	Closed	-$5.67M	–	1905
2024 Q4	$5.67M	Buy	+1,865,000	New	+$8.12M	0.14%	209

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's RVNC Position: Q1 2025 in Review

Boothbay Fund Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,477 shares — an estimated $41K sold.

Boothbay Fund Management first reported a position in RVNC in Q1 2018 and held it in 9 quarters. The position peaked at $701K in Q4 2019. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Boothbay Fund Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 13,477 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $41K.
Boothbay Fund Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
Boothbay Fund Management's Revance Therapeutics, Inc. position peaked at $701K in Q4 2019.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.